Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 7/20 | 0.55 |
| ▸ | DHODH | Q02127 | 5/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2717882 | 0.89 | DHODH (0.54) | PLA2G2ADHODHPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2717536 | 0.87 | PDE10A (0.48) | PLA2G2ADHODHPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2716715 | 0.87 | DHODH (0.60) | PLA2G2ADHODH | |
| SCHEMBL6122986 | 0.82 | PLA2G2A (0.44) | PLA2G2ADHODHPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2718336 | 0.79 | PIK3CD (0.48) | DHODHPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1695154 | 0.78 | PLA2G2A (0.54) | PLA2G2ADHODHPDE10A | |
| SCHEMBL20081373 | 0.78 | FABP3 (0.44) | DHODHPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2718949 | 0.77 | PIK3CD (0.58) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2720107 | 0.77 | PIK3CD (0.57) | PLA2G2ADHODHPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2720602 | 0.76 | PIK3CD (0.53) | PLA2G2ADHODHPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873704-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873704-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873704-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160333017-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160333017-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160333017-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2016-11-17 | — | — | US | disclosed |
| EP-2445900-B1 | POLYCYCLIC DERIVATIVES OF PYRIDINE AND THEIR USE IN THE TREATMENT OF (INTER ALIA) RHEUMATOID ARTHRITIS AND SIMILAR DISEASES | AMGEN INC (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2445900-B1 | POLYCYCLIC DERIVATIVES OF PYRIDINE AND THEIR USE IN THE TREATMENT OF (INTER ALIA) RHEUMATOID ARTHRITIS AND SIMILAR DISEASES | AMGEN INC (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2445900-A2 | POLYCYCLIC DERIVATIVES OF PYRIDINE AND THEIR USE IN THE TREATMENT OF (INTER ALIA) RHEUMATOID ARTHRITIS AND SIMILAR DISEASES | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010151740-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151740-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PLA2G2A 298/4885DHODH 3116/4885PIK3CD 15/4885 |
| US-20160333017-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PLA2G2A 289/4885DHODH 3134/4885PIK3CD 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.